Swiss drugmaker Roche has launched final-stage human trials for zosurabalpin, a breakthrough antibiotic targeting deadly drug-resistant infections like sepsis and pneumonia. Developed with Harvard, the drug combats Acinetobacter baumannii, deemed an "urgent threat" by the CDC. If successful, it could be approved by the decade’s end, offering hope in the fight against antimicrobial resistance.